Table 2.
Quality-of-life measurements
| SAP | TAP | P* | |||
|---|---|---|---|---|---|
| Baseline | 12 months | Baseline | 12 months | ||
| Disease-specific HRQoL | n = 183 | n = 190 | |||
| ȃVEINES-QOL | 43.3 (41.9, 44.7) | 52.7 (51.9, 53.9) | 43.0 (41.6, 44.3) | 53.8 (53.3, 55.1) | 0.394 |
| ȃVEINES-Sym | 41.9 (40.5, 43.3) | 53.5 (52.6, 54.4) | 41.3 (39.9, 42.7) | 54.2 (54.0, 55.6) | 0.514 |
| Generic HRQoL | n = 186 | n = 195 | |||
| ȃEQ-5D™ | 0.808 (0.779, 0.838) | 0.931 (0.911, 0.950) | 0.820 (0.796, 0.844) | 0.939 (0.921, 0.956) | 0.540 |
| ȃEQ-VAS | 77.7 (75.5, 79.5) | 81.6 (79.7, 83.5) | 76.3 (74.3, 78.3) | 82.6 (81.0, 84.1) | 0.444 |
Values are mean (95% c.i.). SAP, isolated ambulatory phlebectomy with or without delayed endovenous truncal ablation; TAP, thermal ablation with concomitant phlebectomy; HRQoL, health-related qualtiy of life; VEINES-QOL/Sym outcomes VEnous INsufficiency Epidemiological and Economic Study Quality of Life/Symptoms; EQ-5D™, EuroQol Five Dimensions; EQ-VAS, EuroQol visual analogue scale. VEINES-QOL/Sym outcomes were analysed in a multilevel repeated-measures model. EQ-5D™ and EQ-VAS scores were analysed using an independent t test. *SAP versus TAP at 12 months’ follow-up.